CAMURUS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 676.5 SEK | +4.08% |
|
+6.03% | +25.74% |
| 02:00pm | Transcript : Camurus AB, Q2 2024 Earnings Call, Jul 16, 2024 | |
| 07:00am | Tranche Update on Camurus AB (OM:CAMX)'s Equity Buyback Plan announced on June 28, 2024. | CI |
Presentation Operator MessageOperator (Operator)Welcome to Camurus' Q2 report for 2024. [Opera...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Companyâs products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.
Sector
Pharmaceuticals
Calendar
2024-07-15
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
650
SEK
Average target price
624.8
SEK
Spread / Average Target
-3.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.74% | 3.6B | |
| +62.80% | 856B | |
| +38.95% | 631B | |
| -4.15% | 359B | |
| +17.51% | 325B | |
| +8.62% | 297B | |
| +5.89% | 234B | |
| +16.53% | 226B | |
| +15.29% | 177B | |
| +1.97% | 165B |
- Stock Market
- Equities
- CAMX Stock
- News Camurus AB
- Transcript : Camurus AB, Q2 2024 Earnings Call, Jul 16, 2024
